Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. The leading brand of Tamiflo D range being promoted by Edinburgh Pharmaceuticals in India.

-

 

Abstract

Background

We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year.




Methods

Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The data was evaluated and statistically analyzed by using RevMan version 5.3.0.




Results

Five studies including 4348 patients were studied. The analysis found that the combination group was significantly greater effect in international prostate symptom score (mean difference [MD], − 1.43; 95% confidence interval [CI], − 2.20 to − 0.66; P = 0.0003), prostate volume (MD, − 10.13; 95% CI, − 12.38 to − 7.88; P < 0.00001), transitional zone volume (MD, − 3.18; 95% CI, − 3.57 to − 2.79; P<0.0001), maximum urine flow rate (MD, 1.05; 95% CI, 0.82 to 1.29; P < 0.00001), prostate specific antigen (MD, − 0.54; 95% CI, − 0.80 to − 0.29; P < 0.0001) and post-void residual volume (MD, − 3.85; 95% CI, − 4.95 to − 2.76; P < 0.00001) compared with the tamsulosin group. In terms of safety, including adverse events (odds ratio [OR], 2.06; 95% CI, 1.34 to 3.17; P = 0.001), erectile dysfunction (OR, 2.24; 95% CI, 1.73 to 2.92; P < 0.00001), ejaculation disorder (OR, 3.37; 95% CI, 1.97 to 5.79; P < 0.0001), retrograde ejaculation (OR, 2.30; 95% CI, 1.08 to 4.93; P = 0.03), decreased libido (OR, 2.25; 95% CI, 1.53 to 3.31; P < 0.0001) and loss of libido (OR, 3.38; 95% CI, 1.94 to 5.88; P<0.0001), the combination group showed poor tolerance than the tamsulosin group with the exception of dizziness (OR, 1.16; 95% CI, 0.75 to 1.80; P = 0.50). The combination group significantly reduced the risk of clinical progression than the tamsulosin group especially in incidence of BPH-related symptom progression (OR, 0.56; 95% CI, 0.46 to 0.67; P < 0.00001) and acute urinary retention (OR, 0.61; 95% CI, 0.38 to 0.98; P = 0.04).





Conclusion

The combination of tamsulosin plus dutasteride provides a preferable therapeutic effect for BPH with a higher incidence of sexual side effects, but combination-therapy can markedly reduce risk of BPH-related symptom progression and acute urinary retention relative to tamsulosin monotherapy.





Courtesy 

  • Zhongbao Zhou, 
  • Yuanshan Cui, 
  • Jitao Wu, 
  • Rui Ding, 
  • Tong Cai & 
  • Zhenli Gao 

    • BMC Urology 19, Article number: 17 (2019) Cite this article

    • 13k Accesses

    • 19 Citations

    • 3 Altmetric

    • Metrics


    Get More Information Click On This Website Link - www.edinburghpharma.in and QR Code

    volume


    Click on Social Accounts - Facebook , LinkedIn & YouTube 



    #Pharma Franchise in Odisha #Anti-Diabetic PCD# Best PCD Pharma Franchise Company# High Quality Pharma Product# Third Party manufacturing # Top 10 Pharma Franchise# PCD in Uttar Pradesh# Monopoly Phama PCD# Best Pharma Franchise # PCD in Assam# Phama Franchise in Andhra Pradesh, top Pcd Pharma Franchise in India, Medicine Franchise Company List, Pharmaceutical Manufacturing Companies Near Me, Pcd Pharma Franchise Company in Gujarat, Best Pharma Companies, Best Derma PCD Franchise 


    Comments

    Post a Comment

    Popular posts from this blog

    Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Leading Brands Available in India for Dapagliflozin + Sitagliptin + Metformin is SITPIN DM Promoted by Edinburgh Pharmaceuticals.

    -
    Image
    Abstract Introduction:  This study compared efficacy and safety of triple drug fixed-dose combination (FDC) of dapagliflozin (DAPA) + sitagliptin (SITA) + metformin (MET) extended release (ER) with SITA + MET sustained release (SR) and DAPA + MET ER in patients with type 2 diabetes poorly controlled with metformin. Methods:  This phase 3, randomized, open-label, active-controlled study included adult patients with glycated hemoglobin (HbA1c) ≥ 8% (64 mmol/mol) and ≤ 11% (97 mmol/mol), randomized in 1:1:1 ratio to receive either FDC of DAPA + SITA + MET ER (10 mg + 100 mg + 1000 mg) tablets once daily (n = 137) or co-administration of SITA + MET SR (100 mg + 1000 mg) tablets once daily (n = 139) or FDC of DAPA + MET ER (10 mg + 1000 mg) tablets once daily (n = 139). Primary endpoint was mean change in HbA1c from baseline to week 16. Results:  Mean baseline HbA1c was approximately 9% (75 mmol/mol) in each treatment group. At week 16, adjusted mean reduction in HbA1c from ba...
    Read more

    Monteflo 3D ( Montelukast + Fexofenadine + Acebrophylline ) from Edinburgh Pharmaceutical

    -
    Image
    Montelukast + Fexofenadine + Acebrophylline is a combination of three medicines: Montelukast, Fexofenadine and Acebrophylline. Montelukast is a leukotriene antagonist. It works by blocking the action of leukotriene, a chemical messenger.  This reduces inflammation in the airways and nose, and improves symptoms of allergies. Fexofenadine is an antiallergic which relieves symptoms like runny nose, watery eyes and sneezing. Acebrophylline is a mucolytic which thins and loosens mucus (phlegm), making it easier to cough out. Courte sy  Dr. Sakshi Sharma , Dr. Ashish Ranjan Get More Information Click On This Website Link  -  www.edinburghpharma.in   and  QR Code Click on Social Accounts - Facebook , LinkedIn & YouTube  Keywords :   #Pharma Franchise in Odisha #Anti-Diabetic PCD# Best PCD Pharma Franchise Company# High Quality Pharma Product# Third Party manufacturing # Top 10 Pharma Franchise# PCD in Uttar Pradesh# Monopoly Phama PCD# Best...
    Read more